Mizuho Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $18

Benzinga Newsdesk www.benzinga.com Positive 59.3%

Neg 0% Neu 0% Pos 59.3%

Mizuho analyst Joseph Catanzaro initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $18.